Tag: drug safety

Inspection-Ready Documentation Standards for Communication with IRB/Regulators Inspection-Ready Documentation Standards for Communication with IRB/Regulators Introduction Effective communication with Institutional Review Boards (IRB) and regulatory authorities is critical in the landscape of clinical trials, particularly when it concerns the standards for documentation. The nuances of these communications vary depending on the geographic region, including the US,…

Read More “Inspection-Ready Documentation Standards for Communication with IRB/Regulators” »

KRIs, KPIs and Dashboards to Monitor Communication with IRB/Regulators Across Portfolios KRIs, KPIs and Dashboards to Monitor Communication with IRB/Regulators Across Portfolios Introduction to Key Risk Indicators (KRIs), Key Performance Indicators (KPIs), and Dashboards In clinical research, effectively monitoring communication with Institutional Review Boards (IRBs) and regulatory authorities is critical. This monitoring ensures compliance with…

Read More “KRIs, KPIs and Dashboards to Monitor Communication with IRB/Regulators Across Portfolios” »

Case Studies: Communication with IRB/Regulators That Strengthened Safety Oversight Effective communication with Institutional Review Boards (IRBs) and regulatory agencies is essential for ensuring patient safety and regulatory compliance in clinical trials. As professionals in clinical operations, regulatory affairs, and medical affairs, understanding how to navigate these communications can significantly influence the efficacy of trial oversight….

Read More “Case Studies: Communication with IRB/Regulators That Strengthened Safety Oversight” »

Common Pitfalls in Communication with IRB/Regulators—and How to Avoid Regulatory Findings Effective communication with Institutional Review Boards (IRBs) and regulatory agencies is critical for the successful conduct of clinical research trials. Navigating the regulatory landscape can be challenging, particularly given the complexities and nuances involved in obtaining approvals, reporting changes, and maintaining compliance with evolving…

Read More “Common Pitfalls in Communication with IRB/Regulators—and How to Avoid Regulatory Findings” »

Aligning Communication with IRB/Regulators With GCP, ICH E2A–E2F and Local Regulations In the domain of translational clinical research, effective communication with Institutional Review Boards (IRBs) and regulators is critical for the success of clinical trial operations. This article serves as a comprehensive guide, structured step-by-step, to navigate the complexities of aligning communication with regulatory bodies…

Read More “Aligning Communication with IRB/Regulators With GCP, ICH E2A–E2F and Local Regulations” »

Digital Tools and Automation to Streamline Communication with IRB/Regulators Digital Tools and Automation to Streamline Communication with IRB/Regulators The landscape of clinical trials is evolving rapidly, particularly in the domains of communication with Institutional Review Boards (IRBs) and regulatory authorities. As organizations like Amgen advance their clinical trials, including the integration of real-world evidence (RWE)…

Read More “Digital Tools and Automation to Streamline Communication with IRB/Regulators” »

Communication with IRB/Regulators: End-to-End Compliance Framework for Global Clinical Trials Communication with IRB/Regulators: End-to-End Compliance Framework for Global Clinical Trials Effective communication with Institutional Review Boards (IRBs) and regulatory authorities is critical for the success of clinical trials. This article provides a comprehensive step-by-step tutorial on establishing a robust communication strategy to navigate the complexities…

Read More “Communication with IRB/Regulators: End-to-End Compliance Framework for Global Clinical Trials” »

How to Design Communication with IRB/Regulators That Meets FDA, EMA and MHRA Expectations How to Design Communication with IRB/Regulators That Meets FDA, EMA and MHRA Expectations Effective communication with Institutional Review Boards (IRBs) and regulators such as the FDA, EMA, and MHRA is crucial in the context of conducting clinical trials. This article provides a…

Read More “How to Design Communication with IRB/Regulators That Meets FDA, EMA and MHRA Expectations” »

Communication with IRB/Regulators in Practice: Step-by-Step Guide for Sponsors and CROs Communication with IRB/Regulators in Practice: Step-by-Step Guide for Sponsors and CROs Effective communication with Institutional Review Boards (IRBs) and regulatory authorities is paramount in the realm of clinical research trials. In the context of kcr clinical research, it is vital for sponsors and Contract…

Read More “Communication with IRB/Regulators in Practice: Step-by-Step Guide for Sponsors and CROs” »